ACRV vs. VTGN

Last updated Apr 1, 2026

Compare and contrast key facts about Acrivon Therapeutics Inc. Common Stock (ACRV) and VistaGen Therapeutics, Inc. (VTGN).

Performance

ACRV vs. VTGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Acrivon Therapeutics Inc. Common Stock (ACRV) and VistaGen Therapeutics, Inc. (VTGN). The values are adjusted to include any dividend payments, if applicable.

ACRV vs. VTGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
ACRV Acrivon Therapeutics Inc. Common Stock	-42.32%	-59.97%	22.36%	-57.29%	-30.77%
VTGN VistaGen Therapeutics, Inc.	-13.66%	-77.56%	-42.61%	66.34%	-35.26%

Fundamentals

Market Cap ACRV : $53.53M VTGN : $24.14M
EPS ACRV : -$2.02 VTGN : -$1.83
PB Ratio ACRV : 0.48 VTGN : 0.47
Total Revenue (TTM) ACRV : $0.00 VTGN : $790.00K
Gross Profit (TTM) ACRV : $0.00 VTGN : $318.00K
EBITDA (TTM) ACRV : -$84.11M VTGN : -$68.03M

Returns By Period

In the year-to-date period, ACRV achieves a -42.32% return, which is significantly lower than VTGN's -13.66% return.

ACRV

• 1D: 7.75%
• 1M: -7.95%
• YTD: -42.32%
• 6M: -23.20%
• 1Y: -31.53%
• 3Y*: -52.15%
• 5Y*: —
• 10Y*: —

VTGN

• 1D: 4.73%
• 1M: -2.47%
• YTD: -13.66%
• 6M: -83.90%
• 1Y: -77.14%
• 3Y*: -46.54%
• 5Y*: -61.28%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ACRV vs. VTGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACRV

ACRV Risk / Return Rank: 28
ACRV Sharpe Ratio Rank: 28
ACRV Sortino Ratio Rank: 36
ACRV Omega Ratio Rank: 35
ACRV Calmar Ratio Rank: 19
ACRV Martin Ratio Rank: 20

VTGN

VTGN Risk / Return Rank: 14
VTGN Sharpe Ratio Rank: 12
VTGN Sortino Ratio Rank: 22
VTGN Omega Ratio Rank: 19
VTGN Calmar Ratio Rank: 9
VTGN Martin Ratio Rank: 6

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACRV vs. VTGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Acrivon Therapeutics Inc. Common Stock (ACRV) and VistaGen Therapeutics, Inc. (VTGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ACRV	VTGN	Difference
Sharpe ratio Return per unit of total volatility	-0.29	-0.69	+0.40
Sortino ratio Return per unit of downside risk	0.27	-0.37	+0.64
Omega ratio Gain probability vs. loss probability	1.03	0.93	+0.10
Calmar ratio Return relative to maximum drawdown	-0.66	-0.87	+0.20
Martin ratio Return relative to average drawdown	-1.12	-1.65	+0.53
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ACRV vs. VTGN - Sharpe Ratio Comparison

The current ACRV Sharpe Ratio is -0.29, which is higher than the VTGN Sharpe Ratio of -0.69. The chart below compares the historical Sharpe Ratios of ACRV and VTGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ACRV	VTGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.29	-0.69	+0.40
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.19	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.50	-0.19	-0.31

Correlation

The correlation between ACRV and VTGN is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ACRV vs. VTGN - Dividend Comparison

Neither ACRV nor VTGN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ACRV vs. VTGN - Drawdown Comparison

The maximum ACRV drawdown since its inception was -95.47%, roughly equal to the maximum VTGN drawdown of -99.76%. Use the drawdown chart below to compare losses from any high point for ACRV and VTGN.

Drawdown Indicators

	ACRV	VTGN	Difference
Max Drawdown Largest peak-to-trough decline	-95.47%	-99.76%	+4.29%
Max Drawdown (1Y) Largest decline over 1 year	-57.14%	-89.69%	+32.55%
Max Drawdown (5Y) Largest decline over 5 years	—	-99.51%	—
Current Drawdown Current decline from peak	-94.01%	-99.73%	+5.72%
Average Drawdown Average peak-to-trough decline	-69.27%	-84.16%	+14.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	33.81%	47.24%	-13.43%

Volatility

ACRV vs. VTGN - Volatility Comparison

Acrivon Therapeutics Inc. Common Stock (ACRV) has a higher volatility of 19.87% compared to VistaGen Therapeutics, Inc. (VTGN) at 16.09%. This indicates that ACRV's price experiences larger fluctuations and is considered to be riskier than VTGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACRV	VTGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.87%	16.09%	+3.78%
Volatility (6M) Calculated over the trailing 6-month period	75.44%	172.34%	-96.90%
Volatility (1Y) Calculated over the trailing 1-year period	108.07%	111.79%	-3.72%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	105.27%	320.27%	-215.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	105.27%	241.30%	-136.03%

Financials